The Patent Trial and Appeal Board turned away the first two of four challenges Gilead is bringing against the United States, which says it was the first to patent the use of Truvada to prevent HIV infections.
February 05, 2020 at 07:07 PM
1 minute read
Gilead Sciences Inc. has failed in its initial attempts to invalidate two U.S. patents on HIV prevention.
The U.S. Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) on Wednesday declined to institute administrative review of two patents the government holds on methods for using Gilead’s Truvada medication for HIV prevention.
Presented by BigVoodoo
The National Law Journal Elite Trial Lawyers recognizes U.S.-based law firms performing exemplary work on behalf of plaintiffs.
Law firms & in-house legal departments with a presence in the middle east celebrate outstanding achievement within the profession.
The premier educational and networking event for employee benefits brokers and agents.
A large and well-established Tampa company is seeking a contracts administrator to support the company's in-house attorney and manage a wide...
We are seeking an attorney to join our commercial finance practice in either our Stamford, Hartford or New Haven offices. Candidates should ...
We are seeking an attorney to join our corporate and transactional practice. Candidates should have a minimum of 8 years of general corporat...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
Breaking news and trends for law firm and legal departments about the evolving federal regulations in a volatile political climate.
